Mycophenolate Mofetil/Sodium

Phase 2Small molecule

NNational Institute of Allergy and Infectious Diseases (NIAID)

Mycophenolate Mofetil/Sodium is one of 8 small molecule programs targeting Heart Transplant. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Heart TransplantRecruiting

Heart TransplantPhase 2

Recruiting

Competition

Competitive Landscape

7 competitors in Heart Transplant

#DrugCompanyPhaseTrials

Afinitor

Novartis

Approved

7 2

Lexiscan

Astellas

Approved

1 3

Prograf

VVeloxis Pharmaceuticals

Approved

2 4

Prevymis

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Phase 3

1 5

Nulojix

Bristol-Myers Squibb

Phase 2

1 6

Rayos

RRoxane Laboratories

Phase 2

1 7

Synthroid

IInstitut Jerome Lejeune

Phase 1

1 8

Mycophenolate Mofetil/Sodium

NNational Institute of Allergy and Infectious Diseases (NIAID)

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2028

Phase 2Recruiting

Heart Transplant

NCT06478017

Clinical

Trials by Indication[1]

Heart Transplant1 trial

Belatacept With Delayed Tacrolimus Withdrawal Versus Standard-of-Care Tacrolimus in Heart Transplant Recipients (RTB-013)

Recruiting·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT06478017·66 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Mycophenolate Mofetil/Sodium. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Mycophenolate Mofetil/Sodium compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Mycophenolate Mofetil/Sodium. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — National Institute of Allergy and Infectious Diseases (NIAID) company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: NNational Institute of Allergy and Infectious Diseases (NIAID)

Mycophenolate Mofetil/Sodium

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2028

Trials by Indication[1]

Heart Transplant1 trial

References

Drug Info

Quick Facts

Related News